Stannard et al. showed that Gal-1 inhibition by thiodigalactoside (Figure 2A), a disaccharide, has proven effective in decreasing breast cancer progression when co-administered with vaccine immunotherapy [73,74,75,76]. The gene discussed is LGALS1; the disease is breast cancer.